Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections | Zendy

L. E. Jauregui | Zendy; S. Babazadeh | Zendy; Elyse Seltzer | Zendy; L. Goldberg | Zendy; Dainis Krieviņš | Zendy; Mitchell J. Frederick | Zendy; David Krause | Zendy; I. Satilovs | Zendy; Žilvinas Endzinas | Zendy; J. Breaux | Zendy; W. O'Riordan | Zendy

Open Access

Randomized, Double-Blind Comparison of Once-Weekly Dalbavancin versus Twice-Daily Linezolid Therapy for the Treatment of Complicated Skin and Skin Structure Infections

Author(s) -

L. E. Jauregui,

S. Babazadeh,

Elyse Seltzer,

L. Goldberg,

Dainis Krieviņš,

Mitchell J. Frederick,

David Krause,

I. Satilovs,

Žilvinas Endzinas,

J. Breaux,

W. O'Riordan

Publication year - 2005

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/497271

Subject(s) - dalbavancin , medicine , linezolid , randomized controlled trial , dermatology , double blind , skin infection , staphylococcus aureus , pathology , vancomycin , biology , bacteria , genetics , placebo , alternative medicine

Dalbavancin, a novel lipoglycopeptide with a pharmacokinetic profile that allows weekly dosing, is active against gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). The efficacy of dalbavancin for treatment of skin and skin structure infections (SSSIs) was demonstrated in a phase 2 study.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research